Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mach7 Technologies ( (AU:M7T) ) just unveiled an announcement.
Mach7 Technologies announced the resignation of its Chief Financial Officer, Dyan O’Herne, effective September 30, 2025. Ms. O’Herne, who has been with the company for nine years and served as CFO since January 2023, contributed significantly to strengthening Mach7’s financial and operational framework. The company has initiated a search for a new CFO and will provide updates upon appointment.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, offering advanced data management and diagnostic viewing solutions to healthcare organizations globally. Their flagship product, the Mach7 Enterprise Imaging Solution, integrates a Vendor Neutral Archive, the eUnity Enterprise Diagnostic Viewer, and diagnostic workflow applications, catering to a wide range of healthcare providers from large integrated delivery networks to private radiology practices.
YTD Price Performance: -11.25%
Average Trading Volume: 269,294
Technical Sentiment Signal: Sell
Current Market Cap: A$83.41M
Learn more about M7T stock on TipRanks’ Stock Analysis page.